Oncology (ONC) Community

Community Goals

  • Provide forums for interactions of Community members to foster new relationships and provide interactive scientific discussion on current key issues in oncology.
  • Develop of best practices for Annual Meeting scientific programming proposals that leads to scientifically rich, well-developed collaborative proposals issues in oncology.
  • Utilize social media to post impactful publications or presentations, permit commentary, and promote discussion among members.
  • Standardize criteria to prioritize scientific proposals in collaboration with members of other Communities housed within the Translational & Precision Network.

Join the LinkedIn Group.

Upcoming Webinar:
ASCPT Early Career (EC) Community and Oncology (ONC) Community Members-Only Webinar:
Title: Translational and Clinical Pharmacology Considerations in the Development of Immune-Oncology Drugs
Date and Time: Friday, August 28, 2020, 2:00 pm ET
Speaker: Sree Kasichayanula, PhD
Moderators: Pooja Manchandani, PhD, and Malek Okour, PhD
Description: The presentation will highlight the hallmarks of immuno-oncology drug development and expand on pharmacometrics, clinical pharmacology and statistical strategies to optimize clinical trial design and development of immune-oncology drugs. This will be the first webinar of a three-part series on immune-oncology drug development. Highlights of this session will include:
  • Fundamental biology underpinnings and trajectory of immune-oncology drug development and how this differs from the standard clinical development paradigm in oncology.
  • Role and impact of clinical pharmacology aspects to support immune-oncology drug development for monotherapy and combination.
  • Modeling and simulation strategies and clinical trial designs for early development and pivotal trials.
Registration Link: 

ASCPT Early Development & Drug Safety (EDDS) and Oncology (ONC) Communities Members-Only Webinar
Title: Using Preclinical Data in Phase I Oncology Trials: A Bayesian Decision-Theoretic Approach
Date and Time: Tuesday, September 1, 2020, 11:00 AM ET
Speaker: Haiyan Zheng, PhD
Moderator: Huiming Xia, MSc, PhD
Description: Using preclinical data to specify a prior for the human dose-toxicity model parameter(s) can improve interim dose recommendations and precision for estimating the maximum tolerated dose (MTD). Such advantages, however, must be balanced against the risk that more patients will possibly be treated with excessively toxic doses in the case of a prior-data conflict. This presentation will make a proposal for how to measure and address a prior-data conflict in a sequential study with a small sample size. For learning objectives and additional description information, please click the registration link below.
Registration Link: 

ASCPT Members-Only Webinar presented by the Infectious Diseases (INF) and Oncology (ONC) Communities
Title: Convergence of Therapeutic Approaches in Oncology and HIV to Target Immune Evasion: Integrating Clinical Pharmacology Lessons Learned
Date and Time: Friday, September 25, 2020, 12:00 pm ET
Speakers: Akintunde Bello, PhD, and Islam Younis, PhD
Moderators: Daria Stypinski, PhD, and Mark Dresser, PhD
Description: This special virtual session will bring together experts with experience in immuno-oncology and HIV research. They will address the major lessons learned from each therapeutic area and the goal to accelerate the pace and lesson the challenges of drug development. The participants will gain knowledge in the overlapping mechanisms in HIV and cancer that have made similar treatment strategies possible. Lessons learned will be shared from HIV combination therapy approaches on establishing contributions of regiment components to overall safety and efficacy. Immuno-oncology on dose-optimization challenges in the development of immune checkpoint inhibitors will also be explored.
Registration Link: 

Past Webinars
  • IQ CPLG PWG: Strategies to Address Opportunities in Oncology Pediatric Drug
  • Clinical Pharmacological and Pharmacodynamic Perspectives on the Adverse Events of Cancer Immunotherapy
  • Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Cancer Patients
Community Working Groups
Communications Working Group
Goals: Identify the communications tools, shared content and frequency desired by Community members.
Identify a means for Community members to identify content (publications, presentation links, etc.) for consideration.
Shruti Agrawal, PhD, Working Group Lead
Antoinette Ajavon, PhD, Working Group Member

Forum Working Group 
Goals: Identify the forum (webinar, local face-to-face meetings, etc) structure desired by Community members.
Identify the frequency and timeframe for the forum desired by Community members.
Angela James, PhD, Working Group Lead
Yan Ji, PhD, Working Group Member
Imke Bartelink, PharmD, PhD, Working Group Member
If you are interested in volunteering with the ONC working group, please email Stacy.

Yan Ji, PhD

Community Chair


A Ajavon-Hartmann

Antoinette (Toni) Ajavon-Hartmann, PhD

Community Vice Chair


A James

Angela James, PhD

Community Past Chair



Photo Gallery
Recent News
Contact Us